Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others. Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet...
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.059 | -10.2253032929 | 0.577 | 0.5923 | 0.51 | 52347 | 0.53707444 | CS |
4 | -0.142 | -21.5151515152 | 0.66 | 0.665 | 0.51 | 78487 | 0.57612373 | CS |
12 | -2.582 | -83.2903225806 | 3.1 | 4.25 | 0.5 | 233481 | 0.83581207 | CS |
26 | -7.462 | -93.5087719298 | 7.98 | 9.6 | 0.5 | 560286 | 5.7450334 | CS |
52 | -9.557 | -94.858560794 | 10.075 | 21.5 | 0.5 | 926219 | 9.78935275 | CS |
156 | -51.482 | -99.0038461538 | 52 | 53 | 0.5 | 1374411 | 22.30086852 | CS |
260 | -87.982 | -99.4146892655 | 88.5 | 124.5 | 0.5 | 1828047 | 40.74905114 | CS |
Symbole | Prix | Vol. |
---|---|---|
KULRKULR Technology Group Inc | US$ 4,2452 (24,13%) | 76,82M |
OPTTOcean Power Technologies Inc | US$ 0,4105 (24,89%) | 47,15M |
TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 1,9789 (-0,31%) | 36,31M |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 31,015 (1,76%) | 29,06M |
CTMCastellum Inc | US$ 0,9885 (70,43%) | 27,7M |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales